San Francisco, CA, United States of America

David Carroll

USPTO Granted Patents = 48 (Patent Applications = 3)

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 7.8

ph-index = 17

Forward Citations = 1,063(Granted Patents)

Company Filing History:

47 out of 488

Rigel Pharmaceuticals, Incorporated

patents

1 out of 23

Atex Technologies, Inc.

patents

Years Active: 2006-2025

Loading Chart...

48 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12251497 - Indicator marking technology for textiles (2025-03-18),

2. 11827628 - Compositions and methods for inhibition of the JAK pathway (2023-11-28),

3. 11667611 - Compositions and methods for inhibition of the JAK pathway (2023-06-06),

4. 11230554 - Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds (2022-01-25),

5. 11198689 - Compositions and methods for inhibition of the JAK pathway (2021-12-14),

6. 10941134 - AMPK-activating heterocyclic compounds and methods for using the same (2021-03-09),

7. 10421752 - Compositions and methods for inhibition of the JAK pathway (2019-09-24),

8. 10377742 - AMPK-activating heterocyclic compounds and methods for using the same (2019-08-13),

9. 10259826 - Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds (2019-04-16),

10. 10040766 - Ubiquitination inhibitors (2018-08-07),

11. 9751893 - Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds (2017-09-05),

12. 9732073 - Compositions and methods for inhibition of the JAK pathway (2017-08-15),

13. 9725419 - Cycloalkyl substituted pyrimidinediamine compounds and their uses (2017-08-08),

14. 9598432 - 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents (2017-03-21),

15. 9593082 - Compositions and methods for inhibition of the JAK pathway (2017-03-14),

Title: David Carroll: Innovator in JAK Pathway Research

Introduction

David Carroll is an accomplished inventor based in San Francisco, CA, with an impressive portfolio of 47 patents to his name. He has made significant contributions to the field of pharmaceuticals, particularly in developing innovative treatments that target the JAK pathway, which plays a crucial role in various medical conditions.

Latest Patents

Among his most recent patents, David Carroll has focused on "Compositions and methods for inhibition of the JAK pathway." This invention comprises compounds defined by specific formulas (I-V) and outlines methods for utilizing these compounds to treat conditions that benefit from the modulation of the JAK pathway or the inhibition of JAK kinases, particularly JAK3. These patents represent cutting-edge advancements in therapeutic strategies for conditions impacted by this critical signaling pathway.

Career Highlights

David is currently employed at Rigel Pharmaceuticals, Incorporated, a company recognized for its commitment to developing innovative therapies. His work has been instrumental in advancing the understanding and treatment of diseases associated with the JAK pathway, showcasing his dedication to improving patient outcomes through innovation.

Collaborations

Throughout his career, David has collaborated with notable colleagues such as Rajinder Paul Singh and Ankush Argade. These partnerships have fostered an environment of innovation and creativity, facilitating breakthroughs in their shared research endeavors.

Conclusion

David Carroll's contributions to the field of pharmaceuticals and his extensive patent portfolio underscore his role as a leading inventor in the industry. With ongoing research and development, his work continues to pave the way for new therapeutic options, ultimately benefiting patients and advancing medical science.

This text is generated by artificial intelligence and may not be accurate.